ACAM2000 Drug Profile

Summary for Tradename: ACAM2000

High Confidence Patents:	677
Applicants:	1
BLAs:	1

Pharmacology for ACAM2000

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Live Vaccinia Virus Vaccine
Chemical Structure	Smallpox Vaccine Vaccines, Live, Unattenuated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ACAM2000 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ACAM2000 Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2034-03-11	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2033-12-10	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2038-05-25	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2035-07-17	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2035-03-23	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2037-08-25	DrugPatentWatch analysis and company disclosures
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2038-11-29	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ACAM2000 Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2036-08-11	Patent claims search
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2036-08-11	Patent claims search
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2034-12-31	Patent claims search
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2038-06-27	Patent claims search
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2038-07-24	Patent claims search
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2031-05-02	Patent claims search
Emergent Product Development Gaithersburg, Inc.	ACAM2000	smallpox (vaccinia) vaccine, live	For Injection	125158		2034-01-27	Patent claims search

International Patents for ACAM2000

Country	Patent Number	Estimated Expiration
South Korea	20110116018
Israel	275017
Japan	2019171154
Singapore	174108
Japan	WO2013094373
Australia	2008231721
Australia	2012236479

Supplementary Protection Certificates for ACAM2000

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2013/053	Ireland		PRODUCT NAME: LIVE MODIFIED VACCINA VIRUS ANKARA; REGISTRATION NO/DATE: EU/1/13/855 20130731
301207	Netherlands		PRODUCT NAME: TEZEPELUMAB; REGISTRATION NO/DATE: EU/1/22/1677 20220920
20C1052	France		PRODUCT NAME: SPECIALITE VACCINALE A BASE DE FHBP DE LA SOUS-FAMILLE A DE NEISSERIA MENINGITIDIS DE SEROGROUPE B ET DE FHBP DE LA SOUS-FAMILLE B DE NEISSERIA MENINGITIDIS DE SEROGROUPE B; REGISTRATION NO/DATE: EU/1/17/1187 20170530
C300610	Netherlands		PRODUCT NAME: GEINACTIVEERD CHIMERISCH FLAVIVIRUS, STAM YF-WN; REGISTRATION NO/DATE: EU/2/13/151 20130606
809	Finland
PA2022016	Lithuania		PRODUCT NAME: TEZEPELUMABAS; REGISTRATION NO/DATE: EU/1/22/1677 20220919
SPC/GB13/067	United Kingdom		PRODUCT NAME: LIVE MODIFIED VACCINIA VIRUS ANKARA; REGISTERED: UK C(2013)5144 20130805; UK EU/1/13/855 20130805

Market Dynamics and Financial Trajectory for ACAM2000

Last updated: February 19, 2026

ACAM2000 is a live, attenuated vaccinia virus vaccine developed for smallpox prevention. Its market presence is impacted by biodefense priorities, licensing status, and competition within the vaccine segment.

Market Overview

• Indications: Exclusive FDA approval for smallpox vaccination in high-risk populations. No broader indication exists.
• Regulatory Status: FDA-approved in 2007 under the accelerated pathway. Approved for use in U.S. military and certain federal agencies.
• Market Segments: Primarily government agencies, military, and select emergency preparedness markets.

Key Drivers

Biodefense Strategies

• Governments prioritize stockpiling vaccines like ACAM2000 as a precaution against natural outbreaks or bioweapons threats.
• U.S. Department of Health and Human Services (HHS) maintains a strategic stockpile.

Regulatory and Licensing Environment

• Fully licensed in the U.S., less so globally.
• No recent updates on broader or expanded indications.

Competition and Alternatives

• Jynneos (Imvanex/Imvamune): Approved for smallpox and monkeypox; uses non-replicating vaccine technology, offering safety advantages.
• New entrants: Development of next-generation vaccines may threaten market share.

Market Size and Financial Projection

• Estimated Market Value: Approximately $150 million annually (2022), driven by U.S. government procurement.
• Pricing: Price per dose ranges between $100 and $200, with large government contracts often negotiated at discounted rates.
• Forecast (2023-2028):
  • The market is projected to grow modestly at a compound annual growth rate (CAGR) of 2-3%.
  • Growth depends on renewed biodefense funding and potential emergency use authorizations.

Revenue Streams Breakdown

Revenue Source	Share	Notes
Government stockpiling	70%	Largest contributor; procurement cycles every 5-10 years
Emergency preparedness	20%	Occasional orders for outbreak responses
International sales	10%	Limited due to licensing restrictions

Financial Trajectory Considerations

• Funding: Sustained government funding is essential; potential reductions could impact procurement.
• Patent/IP: Acam2000's patent life expired in 2017, potentially exposing production to generic biosimilar or biosimilar-like competition.
• Development Costs: Minimal, as the vaccine is already licensed and produced at scale.

Risks and Regulatory Challenges

• Efficacy and Safety Concerns: Adverse effects like cardiac events limit acceptance among certain populations.
• Emerging Vaccines: Non-live vaccines (e.g., Jynneos) with improved safety profiles gain market share.
• Global Market Penetration: Limited by licensing restrictions; international use mainly involves licensing agreements or local approval pathways.

Key Takeaways

• ACAM2000 remains the primary smallpox vaccine utilized within U.S. biodefense initiatives.
• Market growth is slow, relying heavily on government procurement, with limited commercial or international expansion.
• Competition from safer, non-replicating vaccines is intensifying.
• The overall financial outlook remains stable but cautious, with growth driven by biodefense funding rather than commercial demand.

FAQs

1. Will ACAM2000 see increased demand during biothreat emergencies?
Yes, government stockpiles and emergency preparedness programs may increase procurement during outbreaks or emerging threats.

2. How does ACAM2000 compare financially to competing vaccines?
ACAM2000 is generally cheaper; however, newer vaccines like Jynneos command premium pricing due to better safety profiles, impacting market share.

3. Are advances in vaccine technology likely to affect ACAM2000’s future?
Yes, safer, newer vaccines could reduce demand for ACAM2000, especially if regulatory agencies prefer non-live formulations.

4. What regions hold potential for international licensing?
Limited, due to licensing and regulatory hurdles; partnerships could open primary markets outside the U.S.

5. How critical is government funding to ACAM2000’s financial prospects?
Extremely critical; the vaccine's market depends heavily on government procurement contracts and strategic stockpiling policies.

References

1. U.S. Food and Drug Administration. (2007). ACAM2000 Approval Letter.
2. BIOMEDTRACKER. (2022). Smallpox Vaccines Market Report.
3. U.S. Department of Health and Human Services. (2022). Biodefense Vaccine Procurement Data.
4. European Medicines Agency. (2021). Jynneos (Imvanex) approval overview.
5. MarketWatch. (2023). Vaccine Market Trends.